Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. HCW Biologics Inc.
  6. News
  7. Summary
    HCWB   US40423R1059

HCW BIOLOGICS INC.

(HCWB)
  Report
Delayed Nasdaq  -  05/16 04:00:00 pm EDT
2.110 USD   +7.11%
05/13Earnings Flash (HCWB) HCW BIOLOGICS Reports Q1 Revenue $3.12M
MT
05/13HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/13HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index

09/20/2021 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index


© S&P Capital IQ 2021
All news about HCW BIOLOGICS INC.
05/13Earnings Flash (HCWB) HCW BIOLOGICS Reports Q1 Revenue $3.12M
MT
05/13HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/13HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highligh..
GL
05/13HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highligh..
AQ
05/05HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary..
GL
05/05HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary..
AQ
04/19HCW Biologics' CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual Inte..
AQ
03/29HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Res..
AQ
03/29HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
More news
Analyst Recommendations on HCW BIOLOGICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -18,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,30x
Yield 2022 -
Capitalization 75,5 M 75,5 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 44
Free-Float 25,0%
Chart HCW BIOLOGICS INC.
Duration : Period :
HCW Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HCW BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,11 $
Average target price 7,00 $
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Hing C. Wong Chief Executive Officer, Secretary & Director
Rebecca Byam Chief Financial Officer
Scott T. Garrett Chairman
Peter R. Rhode Chief Scientific Officer & VP-Clinical Operations
Rick Scott Greene Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HCW BIOLOGICS INC.-9.05%71
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-16.67%43 023
BIONTECH SE-38.39%38 601